NCT02928224 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT02928224
Title	Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)
Acronym	BEACON CRC
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Array BioPharma
Indications	colorectal cancer
Therapies	Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| POL \| NOR \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG

Additional content available in CKB BOOST